Retroperitoneal Well-differentiated (WD) and dedifferentiated (DD) liposarcoma

Authored by Open Medicine, published on 2026-06-03 19:39:37.0

The algorithm is broadly aligned with contemporary WD/DDLPS practice: expert sarcoma-center workup with MDM2 confirmation, surgery as the cornerstone for localized disease, and anthracycline-based systemic therapy as standard first-line for advanced DDLPS. It appropriately distinguishes WD-only disease (generally surgery-focused) from DDLPS (higher metastatic risk and greater role for systemic therapy). The metastatic pathway reflects commonly used later-line agents (eribulin, trabectedin, gemcitabine-based regimens), but the abemaciclib strategy and growth-rate-based selection remain evolving and not yet uniform standard-of-care.

  1. Diagnostic workup (at sarcoma center)
    Suspected WDLPS/DDLPS: Expert pathology review with testing for MDM2 amplification MRI (extremity) or CT abdomen/pelvis (retroperitoneal) CT chest staging Core needle biopsy if needed Multidisciplinary tumor board review Discussion of surgery, radiation, systemic therapy, and clinical trials
    • Retroperitoneal WD/DD Liposarcoma
      • Well differentiated only
        WD liposarcoma is characterized by MDM2/CDK4 amplification, low metastatic potential, and primary local management; this node reflects guideline-based biologic risk stratification between WD and DDLPS.
        • Surgery
          Consider neoadjuvant radiation for large disease (enroll on STRASS trial)
      • Dedifferentiated component
        DDLPS carries higher grade biology and greater metastatic/systemic-therapy relevance than WD disease; major guidelines outline different management considerations for DDLPS.
        • Localised
          • Surgery
            Can consider neoadjuvant chemotherapy + RT to facilitate surgery for select cases.
        • Metastasis
          • Rapid growth
            • Doxorubicin
              Anthracycline-based therapy is the standard first-line systemic option for advanced/metastatic soft-tissue sarcoma, including DDLPS, with doxorubicin as the backbone agent.
              • Subsequent line therapy options
                Consider: Doxorubicin (if not already given) Abemaciclib (if not already given) Trabectedin Eribulin Gemcitabine + Docetaxel Gemcitabine + Dacarbazine Palbociclib Immune checkpoint inhibitor Access, patient goals, performance, etc should be discussed.
          • Slow growth
            • Abemaciclib (SARC041) or Chemotherapy
              CDK4 inhibition is biologically relevant in WD/DDLPS (CDK4 amplification common), but abemaciclib remains investigational for DDLPS; ongoing phase 3 evaluation (SARC041) means this node is trial-based rather than established standard care.
              • Subsequent line therapy options
                Consider: Doxorubicin (if not already given) Abemaciclib (if not already given) Trabectedin Eribulin Gemcitabine + Docetaxel Gemcitabine + Dacarbazine Palbociclib Immune checkpoint inhibitor Access, patient goals, performance, etc should be discussed.
tosprivacySARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma